Business context and reporting period
The supplied filing is Synalloy Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022, filed August 9, 2022. This differs from the request metadata identifying ASCENT INDUSTRIES CO.; confirm the issuer before relying on this summary. Synalloy operates Metals and Specialty Chemicals segments. DanChem, acquired in October 2021, contributed $8.4 million of Q2 sales; Palmer operations were permanently ceased at year-end 2021 and the remaining assets are held for sale.
Key financial results
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Net sales | $116.2M | $83.1M | $232.4M | $152.9M |
| Gross profit / margin | $20.9M / 18.0% | $14.1M / 17.0% | $43.4M / 18.7% | $22.8M / 14.9% |
| Operating income | $12.2M | $4.1M | $25.4M | $6.2M |
| Net income | $11.1M | $2.9M | $21.3M | $4.0M |
| Diluted EPS | $1.06 | $0.31 | $2.05 | $0.43 |
| Operating cash flow | Not separately reported | Not separately reported | $2.9M | $5.0M |
Q2 revenue increased 40.0%, while average selling prices rose 60.2% and pounds shipped fell 14.9%. Excluding DanChem, sales rose 29.8%. Six-month sales grew 52.0%; average selling prices increased 59.4% while pounds shipped decreased 6.6%. Management attributed earnings growth largely to price increases and raw-material cost pass-through, with productivity also contributing. Q2 operating income rose 200.8%; six-month operating income rose 312.6%.
Liquidity, debt and cash flow
At June 30, 2022, cash was $0.2M, current assets $204.4M and current liabilities $72.0M; the reported current ratio was 2.8. Total long-term debt was $68.3M, including $63.8M drawn on the revolving facility and a $4.5M term loan; an additional $0.9M insurance-premium note payable matures April 2023. The credit facility matures January 2025, bears variable rates (2.15% weighted-average rate at quarter-end), and had $41.2M available capacity. The company reported compliance with debt covenants. Debt-to-capital was 34%, versus 39% at year-end 2021.
Six-month operating cash flow was lower year over year despite higher earnings, principally due to working-capital investment: inventory increased $32.4M and receivables increased $14.3M, partially offset by a $23.6M increase in payables. Investing cash outflow was $2.3M, including $2.3M of property and equipment purchases. Cash fell $1.8M to $0.2M. Management believes liquidity sources can fund operations, expected capital spending and obligations over the next 12 months. Capital spending of up to $6.5M was expected for the remainder of 2022.
Other material changes and unusual items
- DanChem contributed $15.9M of sales and $0.4M of operating income in the first half of 2022. Its acquisition-related costs were $0.7M for the half-year.
- The company released $1.9M of federal deferred-tax valuation allowances after concluding certain deferred tax assets were more likely than not realizable. The resulting effective tax rates were 6.4% for Q2 and 13.5% year to date.
- Earn-out liabilities declined to $0.4M from $2.0M at year-end, largely following payments; fair-value adjustments reduced operating expense by $0.1M in Q2.
- Adjusted EBITDA, a non-GAAP measure, was $15.5M for Q2 and $32.4M for the first half, compared with $9.8M and $14.6M, respectively. Review the company’s reconciliation and adjustments when evaluating this measure.
Outlook, risks and controls
No specific revenue or earnings guidance was provided. Management described continued product demand and profitable growth, while noting inflation, raw-material and freight costs, labor cost increases and persistent labor shortages. COVID-related supply-chain and labor effects remained uncertain; the company cited possible indirect effects of the Russia-Ukraine conflict on commodity and fuel prices and demand, despite no direct operational exposure. The Palmer facility lease obligation extends through 2036; subleasing covers only part of the facility, and the company was seeking a tenant for the remainder.
The company disclosed material weaknesses in internal control over financial reporting identified in its 2021 Form 10-K. Remediation—including finance staffing, training, and stronger inventory, revenue, receivables and close controls—was ongoing and had not yet been demonstrated effective. Management said it could not predict the completion date or guarantee successful remediation. Management reported no known legal matter expected to materially affect results, and no material change in previously disclosed risk factors.
Important facts for investors to verify
- Confirm the filing issuer: the supplied filing is Synalloy Corporation, not ASCENT INDUSTRIES CO.
- Assess whether higher selling prices can continue to offset lower shipment volumes and cost inflation.
- Monitor receivables, inventory, payables and cash conversion; working-capital use substantially constrained first-half operating cash flow.
- Review variable-rate debt, borrowing-base availability, covenant headroom and the 2025 facility maturity.
- Track progress and testing of remediation for the disclosed material weaknesses.
- Evaluate the Palmer lease exposure through 2036 and prospects for subleasing the remaining space.
- Distinguish reported earnings from acquisition effects, the valuation-allowance release and non-GAAP adjusted EBITDA.